President Obama’s final State of the Union address could not have set a better tone for the year ahead for the innovator biopharmaceutical industry.
The direct impact of any State of the Union address is limited at best, and the importance of an eighth...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?